/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2023-07-26 13:50:052023-07-26 13:51:07Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2023-04-11 17:22:132023-04-11 17:22:13Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2023-01-05 17:26:342023-01-05 19:12:40Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2022-09-12 07:00:462022-09-12 07:33:26Fierce Biotech names Synthekine as one of its “Fierce 15” Biotech Companies of 2022
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2022-04-07 08:00:422022-05-19 20:00:09Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2022-02-03 08:00:432022-05-19 20:00:40Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2021-12-23 08:00:292022-05-04 08:56:41Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2021-11-16 19:19:252021-12-10 13:01:28Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform
